Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs CAEL 101 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 09 Aug 2017 According to a Fortress Biotech media release, Columbia filed a second provisional patent application with the USPTO to pursue additional method of treatment claims directed to surprising and positive outcomes observed from the phase 1b part of this trial.
- 04 May 2017 Status changed from recruiting to active, no longer recruiting, according to a Fortress Biotech media release.
- 04 May 2017 According to a Fortress Biotech media release, company expects preliminary data from this trial is mid-2017, and full data by the end of 2017.